pharmexec.com
Treating Disruptive Symptom’s in Crohn’s Patients: Q&A with Mark Genovese, MD
The article reports regulatory approvals and clinical-trial results for Omvoh (mirikizumab), which could offer a new option for people with moderate–severe Crohn’s who still have disruptive symptoms like bowel urgency. It highlights both symptom relief and measures of intestinal healing from company-reported trials.
Adults with moderately to severely active Crohn’s disease, patients interested in biologic options or who have had prior biologic failure, pediatric patients (research in progress), clinicians prescribing IBD therapies, and researchers following IL‑23 pathway drugs.
What To Know
Why it matters Omvoh (a monoclonal antibody targeting the p19 subunit of IL‑23, marketed as mirikizumab) has recent regulatory momentum: the article notes FDA approval in the U.S. for moderately to severely active Crohn’s disease and a positive CHMP opinion from the EMA committee.
The interview with Lilly’s Mark Genovese focuses on how Omvoh may address disruptive Crohn’s symptoms such as bowel urgency, frequent bowel movements, and abdominal pain, and summarizes key trial signals from the VIVID‑1 program.
What to know Omvoh is an IL‑23 p19 inhibitor that was first used in ulcerative colitis and is now discussed for Crohn’s disease based on Lilly’s VIVID‑1 trial results and subsequent regulatory decisions.
The article highlights symptom outcomes (including urgency and frequency), endoscopic and histologic measures of improvement, and longer‑term maintenance data from an open‑label extension mentioned by the company.
Lilly also describes ongoing studies: pediatric trials, long‑term UC studies, a Phase 4 real‑world study in UC, and combination research with another antibody (eltrekibart) in UC. The piece is an industry interview and presents company perspectives on development priorities and trial findings rather than independent clinical analysis.
Implications for patients These developments may expand treatment options for people with moderately to severely active Crohn’s disease, particularly for those struggling with disruptive symptoms, but changes in care depend on regulatory availability, clinician judgment, and access decisions.
This is an interview with a Lilly executive and summarizes company‑reported trial outcomes and regulatory milestones (FDA approval and CHMP positive opinion). The article reflects the company perspective; readers should consult independent trial publications, prescribing information, and regulators for full data and guidance. No new clinical recommendations are provided here.
